Research in contextEvidence before this studyBoth VD3 and AM have been implicated in COPD pathogenesis. However, it is not known whether and how they interact to contribute to COPD pathogenesis.Added value of this studyWe find that VDR is a key transcription factor for AM and a COPD disease gene. We identify that VD3-VDR axis regulates AM homeostasis and function and defect in this regulation results in gradual accumulation of AM, leading to emphysema without overt bronchiolitis.Implications of all the available evidenceOur findings identify the molecular mechanisms by which VD3-VDR regulates AM homeostasis and function, and how the defect in this regulation contributes to specific COPD pathogenesis. Our findings suggest possibilities of inhibiting emphysema in COPD patients by modulating the VD3-VDR axis.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Chronic obstructive pulmonary disease (COPD) is a complex and progressive lung disease, characterized by poor airflow and breathing problems \[[@bb0005]\]. The main pathological features of COPD are emphysema due to destruction of alveolar walls and enlargement of alveoli, and obstructive bronchiolitis (or small airway disease) due to chronic inflammation of peripheral airways and lung parenchyma. Although some COPD patients predominantly have emphysema or obstructive bronchiolitis, patients with severe COPD often exhibit overlapping pathologies. Evidence suggests that the different pathologies may have different underlying mechanisms and possibly different causes \[[@bb0005]\]. For example, obstructive bronchiolitis is predominant in COPD patients associated with inhaling household wood smoke whereas obstructive bronchiolitis and emphysema coexist in COPD patients associated with deeply inhaled cigarette smoke. Globally, the most common cause of COPD is tobacco smoke, but only about 20--50% of smokers ever develop COPD \[[@bb0010], [@bb0015], [@bb0020]\], suggesting contribution of genetic, epigenetic and environmental factors in the development and progression of COPD. Supporting a critical role of environmental factors, most COPD exacerbations are triggered by respiratory infections \[[@bb0025]\]. However, how different factors interact and contribute to the different COPD pathologies at the molecular and cellular levels is largely unknown.

The lung tissue contains two types of macrophages. Alveolar macrophages (AM), which reside in alveoli and function to clear apoptotic cells and inhaled substance and particles, are derived from erythro-myeloid progenitors in the yolk sac and maintained by self-renewal in response to cytokine GM-CSF \[[@bb0030]\]. During lung inflammation, monocytes are also recruited into the lung tissue to generate inflammatory macrophages, which contribute to immune responses and tissue repair and remodeling \[[@bb0035]\]. Macrophages, especially AM, are known to play important roles in COPD pathogenesis \[[@bb0040],[@bb0045]\]. Macrophage numbers are increased by 5-10-fold in bronchoalveolar lavage (BAL) fluid as well as in the airways, parenchyma, and sputum of patients with COPD \[[@bb0050],[@bb0055]\]. Macrophages are often found at the sites of alveolar wall destruction in patients with emphysema, and macrophage numbers in the parenchyma are positively correlated with the severity of emphysema \[[@bb0060]\], raising the possibility that dysfunction of AM is responsible for emphysema. Consistent with this possibility, AM are activated by cigarette smoke, pollutants, and microbes to secrete matrix metalloproteinases (MMPs) 2, 9 and 12, and cathepsins K, L and S, which are directly involved in the destruction of alveolar walls \[[@bb0065]\]. Transcriptional analysis showed that AM in COPD patients are abnormally polarized to express genes involved in tissue remodeling \[[@bb0070],[@bb0075]\]. Following stimulation, AM also secrete cytokines and chemokines, which in turn induce immune cell recruitment, inflammation, mucus hypersecretion, lung tissue damages and remodeling. Furthermore, both AM and monocyte-derived macrophages from COPD patients show reduced phagocytosis of bacteria \[[@bb0080]\]. The impaired elimination of bacteria by AM likely contributes to chronic colonization of low airways by bacteria and therefore increased frequencies of acute exacerbation \[[@bb0085]\]. Despite these observations, the precise role of AM and how their dysfunction contributes to COPD pathogenesis are not fully understood.

1,25-dihydroxyvitamin D~3~ (VD3) is the active ligand of vitamin D receptor (VDR). Upon binding of VD3 to VDR in the cytosol, the heterodimer further interacts with the retinoid X receptor (RXR). The trimeric complex is then translocated into the nucleus to regulate gene transcription through vitamin D response elements (VDRE) present in the enhancers and promoters of responsive genes \[[@bb0090]\]. The VD3-VDR axis has been shown to regulate both innate and adaptive immune responses \[[@bb0095]\] and exert a significant impact on COPD pathogenesis \[[@bb0100],[@bb0105]\]. VD3 deficiency causes impairment of lung structure and function and increased severity of COPD-like diseases in the cigarette smoke-exposed mice whereas VD3 supplementation readily attenuates the disease symptoms and pulmonary inflammation \[[@bb0110], [@bb0115], [@bb0120]\]. In human, VD3-deficiency is also associated with higher risks of COPD susceptibility and more severe impairment of lung function in COPD patients \[[@bb0125], [@bb0130], [@bb0135], [@bb0140]\]. Although conflicting results have been reported on the efficacy of VD3 supplements for treating COPD, large cross-sectional and prospective studies have shown that VD3 deficiency is prevalent in patients with COPD and VD3 supplementation improves lung function and prevents exacerbation of COPD \[[@bb0145],[@bb0150]\]. A possible confounding factor is that COPD is a complex disease with different pathologies and possible underlying mechanisms, but most large population-based studies and clinical cohort studies of VD3 supplements on COPD did not make these distinctions. A mechanistic understanding of how VD3 deficiency contributes to COPD pathogenesis is urgently needed for rationale use of VD3 supplements for managing COPD.

*Vdr* is highly expressed in AM comparing to other tissue macrophages \[[@bb0155]\]. Macrophages are particularly responsive to VD3 to downregulate expression of inflammatory cytokines and chemokines. VDR-deficient (*Vdr*^*−/−*^) mice are viable but exhibit severe bone defects and die prematurely around 16 weeks of age, which could be extended by giving mice calcium and phosphorus supplements \[[@bb0160], [@bb0165], [@bb0170]\]. Although *Vdr*^*−/−*^ mice have no obvious alterations in the immune system in lymphoid organs and peripheral blood \[[@bb0170]\], VDR-deficient macrophages display defects in cellular function and immunity both *in vitro* and *in vivo* \[[@bb0170], [@bb0175], [@bb0180]\]. More recently, *Vdr*^*−/−*^ mice at 16-weeks of age were reported to exhibit premature emphysema with increased secretion of MMPs \[[@bb0185]\], suggesting a role of VDR deficiency in the pathogenesis of emphysema. However, because the mice were deficient in VDR in germline (every cell type) and were given calcium and phosphorus supplements, the cellular and molecular mechanisms underlying the development of emphysema in *Vdr*^*−/−*^ mice are not fully understood.

In this study, we have investigated the mechanisms by which VD3, VDR and AM interact to contribute to COPD pathogenesis. We show: i) VDR is a key transcriptional factor (TF) for AM and a COPD disease gene; ii) VD3-VDR axis inhibits AM proliferation and inflammatory responses; iii) *Vdr*^*−/−*^ mice exhibit a progressive accumulation of AM and concomitant lung emphysema, without gross immune cell infiltration into the lung; iv) intratracheal transfer of *Vdr*^*−/−*^ AM into wildtype mice is sufficient to induce lung emphysema; and v) VD3 inhibits inflammatory responses and oxidative stress of AM induced by heme and LPS. These results show that VD3-VDR axis regulates AM homeostasis and function and defect in this pathway results in emphysema. Thus, our findings identify the molecular and cellular mechanisms by which VD3, VDR, and AM interact to contribute to specific aspect of COPD pathogenesis and provide new insights into the use of vitamin D supplements for treating emphysema.

2. Material and methods {#s0025}
=======================

2.1. Systems biology approaches to identify key transcription factors and key disease genes {#s0030}
-------------------------------------------------------------------------------------------

The methodological framework to identify key TFs for a particular gene set have been established in our previous studies \[[@bb0190]\]. A genome-wide regulatory network of mouse macrophage was assembled based on 1378 gene expression profiles of tissue macrophages, bone marrow-derived macrophages and macrophage cell lines collected from 124 independent GEO data sets (Table 1S) using a reverse-engineering algorithm CLR \[[@bb0195]\]. Microarray datasets from the same platform were uniformly normalized using Robust Multichip Averaging (RMA) and samples from different platforms were integrated and normalized with total intensity. The signature gene sets of different tissue macrophages (Tables S2) were extracted based on a previous study \[[@bb0155]\]. The adipose macrophage signature was extracted from the expression profiles of adipose macrophages from WT and obesity mice \[[@bb0200]\]. Master regulator analysis (MRA) is applied to identify TFs to regulate expression of signature genes of particular tissue macrophages by computing the statistical significance of overlaps of all interactions of each TF (inferred by CLR) with each set of signature or a background gene set by a binomial test. The set of 314 background genes (Tables S2) was identified from the 1378 gene expression profiles based on high levels of gene expression (RMA value \>8.5) with minimal variation among all samples (variation from mean \< 1).

To explore the key disease genes in macrophages for COPD, a high-confident gene functional network of macrophages was assembled using the Bayesian likelihood integration method based on four different whole-genome datasets: 1889 gene expression profiles, protein-protein interaction data (PPI) downloaded from eight databases (Biogrid, BIND, DIP, Complex, HPRD, InAct, MINT, MPPI), protein phylogenetic profiling based on all mouse proteins blastn scores to all other 59 ENSEMBL genomes (<http://ensemblgenomes.org/>) and gene phenotypic data from MGI (<http://www.informatics.jax.org/phenotypes.shtml>). For each gene pair, Pearson correlation coefficient (PCC) based on gene expression profiles, number of interaction observations in 8 PPI datasets, mutual information scores based on phylogenetic profiles, phenotypic similarity based on gene phenotypic data. The likelihood ratios for any gene pairs of each dataset were computed based on the overlap with positive and negative gold standard of the 8th grade GO biology process as previously described \[[@bb0205]\]. 10-fold cross validation was used to determine the cutoff of an integrated likelihood ratio with 90% network confidence (Fig. S1 and Table S3). The training COPD disease genes were extracted from OMINI database and curated from previous publications (Table S4). Network-based multiple algorithms including Random Walk \[[@bb0210]\], flow-based propagation \[[@bb0215]\], Nearest Neighbor \[[@bb0220]\], Short Path \[[@bb0225]\] and Markov chain clustering (MCL) \[[@bb0230]\] were used to prioritize the disease genes based on the functional network and known disease genes. The performance of the predictions was evaluated by plotting precision against recall over various thresholds as described \[[@bb0205]\]. A community-based method by combining multiple algorithms had higher sensitivity and specificity to identify disease genes than any single algorithms.

2.2. Mice, antibodies and flow cytometry {#s0035}
----------------------------------------

*Vdr*^*−/−*^ mice, CD45.2 and CD45.1 B6 mice were purchased from the Jackson Laboratory and maintained in the animal facility at the Massachusetts Institute of Technology. All animal studies and procedures were approved by the Massachusetts Institute of Technology\'s Committee for Animal Care. Antibodies specific for CD11c (N418), CD11b (M1/70), F4/80 (BM8), MHC-II (M5/114.15.2), CD45.2 (104), CD45.1 (A20), CD4 (HK1.4), CD8 (53--6.7), CD19 (1D3) for flow cytometry were from Biolegend. Antibody for Irf4 (3E4) was from eBioscience. Anti-VDR (D2K6W) for immunochemistry staining was from Cell Signaling Technology. Single cell preparation from different organs, staining of cells with fluorophore-conjugated antibodies and analysis of the stained cells using flow cytometry are as described \[[@bb0190]\]. Briefly, cells in single cell suspension were incubated with specific antibodies at 4 °C for 20 min, washed twice, and re-suspended in FACS buffer containing DAPI. Cells were run on BD-LSRII, collecting 20,000 to 100,000 live cells per sample. The data were analyzed by FlowJo.

2.3. Histopathology and immunochemical staining {#s0040}
-----------------------------------------------

Mice were euthanized and lungs tissues were inflated and fixed with 10% neutral-buffered formalin solution (Sigma-Aldrich) for 24 h. The tissues were processed with Tissue Processor (Leica Microsystems) and embedded in paraffin. Sections were cut at 5 μm thickness, mounted on polylysine-coated slides (Thermo Fisher Scientific), de-waxed, rehydrated, and processed for hematoxylin and eosin (H&E) staining according to standard protocol. For immunochemical staining, antigen retrieval was carried out by either microwaving the slides in 0.01 M sodium citric acid buffer (pH 6.0) for 30 min. Sections were then immersed for 1 h in blocking buffer (3% BSA, 0.2% Triton X-100 in PBS), then incubated in primary antibody (made up in blocking buffer) at 4 °C overnight, followed by incubation with secondary antibody conjugated HRP at 4 °C for 1 h. All lung stained sections were scanned with a high-resolution Leica Aperio Slide Scanner. Images were analyzed by WebScope software.

2.4. Alveolar macrophage isolation, culture and adoptive transfer {#s0045}
-----------------------------------------------------------------

GM-CSF is known to promote proliferation and maintain the global gene transcription and function of AM *in vitro* and *in vivo* \[[@bb0235], [@bb0240], [@bb0245]\]. In our study, AM were isolated from mice as described \[[@bb0250]\]. To expand AM numbers, freshly isolated AM were cultured in complete RPMI (RPMI 1640 supplemented with 10% FBS, 5 mM HEPES, 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen)) supplemented with 25 ng/mL murine GM-CSF (Peprotech). Detailed culture and treatment conditions of AM with or without 50 nM VD3 for other assays were described in the text. For adoptive transfer experiment, 5 × 10^5^ *Vdr*^*−/−*^ AM (CD45.2^+^) after expansion *in vitro* for one week were adoptively transferred into 8-week-old CD45.1^+^ C57BL/6 (B6) mice intratracheally every week for a consecutive four weeks. Mice were analyzed at the sixth weeks following transfer. Unless specified, AM refers to mouse alveolar macrophages throughout the text.

2.5. Human alveolar macrophage isolation {#s0050}
----------------------------------------

Human alveolar macrophages were isolated by bronchoalveolar lavage (BAL) from normal volunteers with a lifetime non-smoking history, no acute or chronic illness, and no current medications. The lavage procedure used two or three 20-ml aliquots of sterile, warmed saline in right middle or left lingular lobe of the lung. The lavage fluid was filtered through two layers of gauze and centrifuged at 500 *g* for 5 min. The cell pellet was washed twice in PBS and suspended in complete RPMI. Cells were seeded on cell culture plates for 20 min and non-adherent cells were collected with purity of alveolar macrophages ranging from 90 to close to 100% based on Giemsa staining and flow cytometry. All protocols were approved by the Ethics Committee of The First Affiliated Hospital, Jilin University. All experiments were performed in accordance with the relevant guidelines and regulations. In addition, written informed consent was obtained from each subject.

2.6. Heme measurement and cellular ROS {#s0055}
--------------------------------------

Heme concentration in BAL was quantified using a fluorescence assay as previously described \[[@bb0255]\]. Briefly, BAL was collected by one-time washing with 1 mL PBS supplement with 2 mM EDTA for one mouse lung. BAL was cleaned by centrifuge at 1500 *g* for 5 min. 50 μl of BAL fluid was mixed with 200 μL 2 M oxalic acid. Samples as well as heme standards (0 to 100 nM) were heated at 95 °C for 30 min to remove iron from heme. The resultant protoporphyrin was detected using a fluorescence microplate reader (Tecan Infinite M200 Pro). Heme concentration in each sample was calculated based on the heme standards. Intracellular total ROS were quantified directly by flow cytometry using the broad free radical probe CM-H2DCFDA (Molecular Probes). Cells were incubated with 5 mM H2DCFDA in complete RPMI at 37 °C for 30 min.

2.7. RNA isolation, RNA sequencing and data analysis {#s0060}
----------------------------------------------------

AM were isolated from *Vdr*^*−/−*^ mice and wild type littermates. Freshly isolated wildtype AM were treated with or without 50 nM VD3 for 24 h in the complete RPMI medium supplemented with 25 ng/mL murine GM-CSF (Peprotech). RNAs were extracted with RNeasy MiniElute kit (Qiagen), converted into cDNA and sequenced using Next-Generation Sequencing (Illumina). Raw sequences are deposited in the database of Gene Expression Omnibus (GEO) with accession ID: [GSE124725](ncbi-geo:GSE124725){#ir0015}. RNAseq data was aligned to the mouse genome (version mm10) and raw counts of each gene of each sample were calculated with bowtie2 2.2.3 \[[@bb0260]\] and RSEM 1.2.15 \[[@bb0265]\]. Differential expression analysis was performed using the program edgeR at *P* \< .05 with a 2 fold-change \[[@bb0270]\]. The gene expression level across different samples was normalized and quantified using the function of cpm. Differentially expressed genes were annotated using online functional enrichment analysis tool DAVID (<http://david.ncifcrf.gov/>) \[[@bb0275]\]. Gene set enrichment analysis were performed with GSEA \[[@bb0280]\] with FDR q-value\<0.05. The heatmap was visualized with MeV \[[@bb0285]\]. To validate and quantify the levels of RNA transcripts, total RNA was extracted from various cells and reverse transcribed by TaqManÂ® Reverse Transcription Reagents Kit (ABI Catalog No. N8080234), followed by amplification with Sybr Green Master Mix (Roche Catalog No. 04707516001) with specific primers (Table S5) and detected by Roche LightCycler 480. The Ct values were normalized with housekeeping gene GAPDH for comparison.

2.8. ChIP, sequencing and analysis {#s0065}
----------------------------------

Freshly isolated AM (1 × 10^6^) were cultured and expanded in complete RPMI supplemented with 25 ng/mL murine GM-CSF (Peprotech) for 2 weeks. Chromatin immunoprecipitation (ChIP) was performed using the SimpleChIP (Cell Signaling Technology) following the manufacture\'s manual. Briefly, 20 × 10^6^ AM were treated with formaldehyde at a final concentration of 1% to cross-link DNA-protein complexes. Cells were lysed and DNA-protein complexes were sheared by micrococcal nuclease, followed by precipitation with nonspecific rabbit anti-IgG or Anti-VDR (D2K6W) (Cell Signaling Technology. Eluted and purified ChIP DNA was used to prepare the DNA-sequencing libraries with the NEBnext ChIPSeq library Prep kit (NEB) for Next-Generation Sequencing (Illumina). Raw sequencing data was deposited in GEO with accession ID: [GSE124725](ncbi-geo:GSE124725){#ir0025}. ChIP-seq were analyzed with the software package HOMER \[[@bb0290]\].

2.9. Co-immunoprecipitation {#s0070}
---------------------------

Plasmids of pCDNA3.1 with murine Vdr-HA, Pu.1-FLAG, Fra1-6xHis, Cebpa-Myc and Pparg-FLAG were purchased from GeneScript (USA). For the co-immunoprecipitation, Pu.1-FLAG, Fra1-6xHis, Cebpa-Myc and Pparg-FLAG were co-transfected with HA-tagged Vdr into 293 T cells using TransIT®-LT1 Transfection Reagent (Mirus). 48 h after transfection, the cells were lysed with cold Lysis Buffer containing 20 mM Tris-HCl (PH 7.4), 150 mM NaCl, 0.1% NP-40, 10% glycerol, proteinase inhibitor (Roche Catalog No. 11836153001), and phosphatase inhibitors (Roche Catalog No. 04906845001). The clear supernatants from the lysate were incubated with anti-HA magnetic beads (Thermo Fisher, \#88836) at room temperature for 30 min in the presence or absence of VD3. Then the beads were washed four times and eluted with loading buffer for Western blotting. Eluted proteins were detected by anti-HA (CST, \#2999S), anti-FLAG (Sigma, \#M8823), anti-His (CST, \#2365) and anti-Myc (Genetex, GT0002).

2.10. Statistic methods {#s0075}
-----------------------

Statistical significance was determined with the two-tailed unpaired or paired Student\'s *t*-test. The FDRs were computed with *q* = *p*\**n*/*i,* (*p* = *P* value, *n* = total number of tests, *i* = sorted rank of *P* value).

3. Results {#s0080}
==========

3.1. Systems biology analyses predict vitamin D receptor as a key transcriptional factor for alveolar macrophages and a COPD disease gene {#s0085}
-----------------------------------------------------------------------------------------------------------------------------------------

We have previously developed a network approach to identify key TFs for a particular cell state \[[@bb0190]\] and used the same approach to identify key TFs for macrophages in different tissues. A genome-wide regulatory network of mouse macrophages was assembled based on 1378 transcription profiles of 124 independent macrophage GEO data sets (Table S1) using a reverse-engineering algorithm CLR \[[@bb0195]\]. We identified lineage-specific key TFs for macrophages from seven different tissues using the regulatory network and the signature gene sets from public data ([Fig. 1](#f0005){ref-type="fig"}a, Table S2). *Vdr*, *Spic*, *Nr4a3*, *Gata6*, *Foxm1, Sox4* and *Nfib* were identified as the top key TFs for alveolar macrophages (AM), spleen red-pulp macrophages (RPM), small intestine macrophages (SIM), peritoneal cavity macrophages (PCM), bone marrow macrophages (BMM), microglia, and adipose tissue macrophages (ATM), respectively ([Fig. 1](#f0005){ref-type="fig"}b, see Table S6 for a complete list). *Spic* and *Gata6* are known lineage-specific key TFs for the development and function of RPM and PCM, respectively \[[@bb0295], [@bb0300], [@bb0305], [@bb0310]\]. We confirmed the expression of *Vdr*, *Spic*, *Gata6*, and *Foxm1* in freshly purified AM, RPM, PCM and BMM, respectively, by quantitative RT-PCR (qPCR) ([Fig. 1](#f0005){ref-type="fig"}c and Fig. S2). VDR protein was also highly expressed in AM comparing to other cell types in the lung (Fig. S3). *Mafb* and *Pparg* were identified as top key TFs for the macrophage consensus signature ([Fig. 1](#f0005){ref-type="fig"}b), which is either required for the terminal differentiation of monocytic progenitors to macrophages \[[@bb0315],[@bb0320]\] or a master regulator to maintain the anti-inflammatory phenotype of tissue macrophages \[[@bb0325],[@bb0330]\]. Together, these findings support our network approach to identify key TFs for tissue-resident macrophages.Fig. 1VDR is predicted as a key TF in AM and COPD disease gene. **a**, schematic diagram depicting systems biology approaches to identify the key TFs in tissue-resident macrophages and COPD-disease genes in AM. MRA: master regulatory analysis; PPI: protein-protein interaction; SG: signature genes. b, top-ranked key TFs for each of the seven tissue macrophages and for all seven tissue macrophages. \#SG, number of signature genes; AM, alveolar macrophages; RPM, red pulp macrophages; PCM, peritoneal cavity macrophages; SIM, small intestine macrophages; BMM, bone marrow macrophages; ATM, adipose tissue macrophages; Common to Mϕ, common TF for all seven types of tissue macrophages. **c**, Comparison of the transcript levels of *Vdr*, *Spic*, *Gata6* and *Foxm1* in freshly purified AM, RPM, PCM, BMM, B cells (B) and CD8^+^ T cells (CD8) by qPCR. Data were average of 3 biological replicates per group. **d**, Comparison of the precision rates of community algorithm *versus* other algorithms for identifying COPD-disease genes. **e**, Top ranked key COPD-disease genes in AM. Shaded ones are known COPD disease genes and the others are newly identified in this study. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 1

Because AM play critical roles in the pathogenesis of COPD \[[@bb0005],[@bb0040],[@bb0045]\], we investigated whether the key TFs for AM are potential COPD disease genes using a systems biology approach. We constructed a high-confident gene functional network of macrophages by a Bayesian integration method \[[@bb0205]\] using mouse macrophage expression data, protein-protein interaction (PPI) data, gene phenotype data and phylogenetic data (Fig. 1S and Table S3). The functional network was then applied to prioritize potential novel COPD disease genes using a community method by integrating five different algorithms with 19 known COPD disease genes curated from OMINI database and previous publications ([Fig. 1](#f0005){ref-type="fig"}a and Table S4). This method had a significantly higher precision than other widely used algorithms ([Fig. 1](#f0005){ref-type="fig"}d). Seven of the top 10 genes identified are known COPD disease genes ([Fig. 1](#f0005){ref-type="fig"}e, see Table S7 for a complete list), supporting the validity of our approach. *Vdr,* the key TF for AM, is inferred as one of novel COPD disease genes.

3.2. VD3-VDR regulates diverse sets of gene expression in AM {#s0090}
------------------------------------------------------------

We determined the effect of VD3 on AM at transcription level by RNA-seq. AM were purified from C57BL/6 (B6) mice and cultured for 24 h in the presence or absence of 50 nM VD3, followed by RNA isolation and sequencing. Differential expression analysis revealed that 332 genes were up-regulated and 306 genes were down-regulated ([Fig. 2](#f0010){ref-type="fig"}a and Table S8), including known VD3-induced genes *Vdr*, *Cyp24a1* and *Spp1*. The up-regulated genes were enriched with phosphorylation (73 genes, *P* = 1.7e-11), signal transduction (77 genes, *P* = 3.4e-10), tissue remodeling (15 genes, *P* = 1.1e-6) and cell death (57 genes, *P* = 8.7e-6), while the down-regulated genes were enriched with immune pathways, including immune response (54 genes, *P* = 1.2e-13), defense response (57 genes, *P* = 1.5e-12), and cytokine production (30 genes, *P* = 6.7e-9) ([Fig. 2](#f0010){ref-type="fig"}b). Gene set enrichment analysis (GSEA) revealed that up-regulated genes were enriched in E2F targets and oxidative phosphorylation and down-regulated genes were enriched in TNFα and IFNγ signaling pathways ([Fig. 2](#f0010){ref-type="fig"}c). VD3-induced transcription changes of selected genes, including *Vdr*, *Irf4*, *Hmox1, Muc5b* and *Vegfa*, were verified by qPCR ([Fig. 2](#f0010){ref-type="fig"}d).Fig. 2Transcriptional regulation by VD3 in AM. **a**, Heatmap of gene expression of 332 up-regulated and 306 down-regulated genes induced by VD3 in AM from two independent experiments. Shown is centralized CPM (counts per million reads). **b**, GO enrichment analysis showing enrichment of certain pathways in the up-regulated and down-regulated genes. GO sets of biological process, number of genes and *P*-value are shown. **c**, GSEA showing samples of enriched gene sets in VD3-treated and untreated AM (q-value \<0.05). **d**, Transcript levels of *Vdr*, *Irf4*, *Muc5b*, *Hmox1* and *Vegfa* in AM with or without VD3 treatment for 24 h. Data were collected from two independent experiments with 4 biological replicates per group. Error bars indicate standard deviation (SD). *P* value was calculated by *t*-test. \* *P* \< .05, \*\* *P* \< .01.Fig. 2

To further confirm the transcriptional regulation by VD3-VDR in AM, we assayed the genome-wide VDR binding sites in AM by ChIP-seq. AM were purified from B6 mice, expanded and then cultured for 24 h in the presence or absence of 50 nM VD3. ChIP-seq identified a total of 6080 peaks associated with 3428 genes (peakscore \>30 & *P* ≤1e-10, Table S9). Functional enrichment analysis of 500 genes with top peak scores showed that similar gene pathways, such as phosphorylation, cell death, signal transduction, immune response were enriched ([Fig. 3](#f0015){ref-type="fig"}a), consistent with GO enrichment analysis of differentially expressed genes ([Fig. 2](#f0010){ref-type="fig"}b). 70% of the VD3 up-regulated genes, including *Vdr*, *Cyp24a1* and *Spp1,* had a peak score larger than 30 (*P* ≤1e-10), whereas only 22% of the VD3 down-regulated genes had a peak score larger than 30 ([Fig. 3](#f0015){ref-type="fig"}b). *De novo* motif analysis showed that the VDR-binding motif was the most abundant and significantly enriched binding motif and present in \~40% peaks ([Fig. 3](#f0015){ref-type="fig"}c). The second most significantly enriched motif (based on *P* value) was for Rxra, a known TF that forms complex with VDR \[[@bb0335]\]. Binding motifs for PU.1, Fra1 (component of AP1 complex) and Cebpa were also found in high frequencies ([Fig. 3](#f0015){ref-type="fig"}c). All the identified VDR, Rxra, Fra1, PU.1, and Cebpa binding motifs were mapped to within 200 bp to each other ([Fig. 3](#f0015){ref-type="fig"}d). Similarly, the VDR peaks overlapped with published binding peaks \[[@bb0340]\] for PU.1, JunB and Cebpa in macrophages ([Fig. 3](#f0015){ref-type="fig"}e).Fig. 3Transcriptional regulation by VDR in AM. **a**, GO enrichment analysis of 500 genes with top-ranked peak scores. GO sets of biological process, number of genes and *P*-value are shown. **b**, Comparison of ChIP-seq peak scores of VDR-binding genes and the fold-changes of the same genes induced by VD3 in AM. Each dot represents one gene. Selected genes (solid dots) are indicated. The number indicate the number of genes in the gated regions. **c**, Enriched sequence motifs in VDR ChIP-seq peaks by *de novo* motif analysis. **d**, Comparison of relative positions of VDR, Rxra, Fra1, PU.1 and Cebpa motifs from ChIP-seq. **e**, Comparison of DNA occupancies of VDR to those published for PU.1, JunB and Cebpa in AM. **f**, DNA occupancies of epigenetic marks in macrophages around VDR-binding peaks. **g**. Co-IP of VDR with Pu.1, Fra1 and Cebpa. 293FT cells were transiently transfected with HA-tagged VDR and FLAG-tagged Pu.1 (*Spi1*), His-tagged Fra1 (*Fosl2*) or Myc-tagged Cebpa as indicated. Cell lysates were precipitated with anti-HA in the presence or absence of VD3, followed by Western blotting with anti-HA, anti-FLAG, anti-His or anti-Myc antibodies. Input is the total cell lysate. The pull-down levels were quantified densitometry and normalized to the input and then the pull-down blots without VD3. Shown are representative gel image and average of pull-down level from three independent experiments.Fig. 3

PU.1 and AP-1 are known key TFs for maintaining macrophage identity through controlling the global macrophage-specific enhancer repertoire \[[@bb0345], [@bb0350], [@bb0355]\]. Cebpa and its cofactor Cebpb bind to enhancers and are key TFs required for regulating macrophage polarization \[[@bb0360],[@bb0365]\]. Since \~40% of VDR binding peaks in AM resided in the intergenic regions, but only \~6% in the promoter region (Fig. S4), we tested whether VDR binding motifs are localized in the enhancer regions. We mapped VDR peaks to the published epigenomic tracks of macrophages \[[@bb0245]\]. As shown in [Fig. 3](#f0015){ref-type="fig"}f, VDR peaks were localized in open chromatins of macrophages with high intensity of active transcription (H3K4me2 and H3K27ac) but not in enriched promoter region (H3K4me1). Moreover, VDR constitutively interacted with Pu.1, Fra1 and Cebpa; and the interactions were enhanced by VD3 ([Fig. 3](#f0015){ref-type="fig"}g). Interestingly, VD3 also promoted the interaction between VDR and Pparg (Fig. S5), which is Rxra competitor but a key TF for the maturation and function of AM \[[@bb0370], [@bb0375], [@bb0380], [@bb0385]\]. Together, these results suggest that in response to VD3, VDR regulates gene expression in AM, partly by forming complexes with Rxra, Pu.1 and Cebpa in the transcription active enhancer regions.

3.3. Mice deficient of VDR develop lung emphysema {#s0095}
-------------------------------------------------

To investigate the physiological roles of VDR in AM, we analyzed AM and lung pathology in *Vdr*^−/−^ mice. Hematoxylin and eosin (H&E) staining of lung sections revealed that *Vdr*^−/−^ mice had significant enlargement of airspace (emphysema) as indicated by increase in the mean linear intercept (MLI) as early as 4 weeks of age as compared to age-matched wildtype and heterozygous littermates ([Fig. 4](#f0020){ref-type="fig"}a-b). However, there was no obvious infiltration of immune cells in the lung ([Fig. 4](#f0020){ref-type="fig"}a) and no significant difference in the frequency and CD44 expression of CD4^+^ T cells, CD8^+^ T cells and B cells in the lung tissue between wildtype and *Vdr*^−/−^ mice ([Fig. 4](#f0020){ref-type="fig"}c and Fig. S6a). Similarly, expression of F4/80, CD11b, CD11c and Siglec-F were similar on AM from both wildtype and *Vdr*^−/−^ mice ([Fig. 4](#f0020){ref-type="fig"}d and Fig. S6b), although MHCII expression was up-regulated on AM from *Vdr*^−/−^ mice at 4 weeks of age (Fig. S6b). The number of AM was similar 2 days after birth between wildtype and *Vdr*^−/−^ mice, but was significantly increased in *Vdr*^−/−^ mice by 4 weeks of age and kept on increasing until 7--10 weeks of age ([Fig. 4](#f0020){ref-type="fig"}d-e). AM proliferated in response to GM-CSF and this proliferation was inhibited by addition of VD3 and abolished by *Vdr* deletion ([Fig. 4](#f0020){ref-type="fig"}f). Remarkably, intratracheal transfer of CD45.2^+^ *Vdr*^−/−^ AM into wildtype mice (CD45.1^+^, once per week for four weeks) also led to significant enlargement of airspace ([Fig. 4](#f0020){ref-type="fig"}g-i and Fig. S7), although a single adoptive transfer of *Vdr*^−/−^ AM into wildtype mice failed to induce emphysema probably due to low persistence of the transferred AM (Fig. S7). Together, these results show that by regulating gene expression in AM, VD3-VDR axis plays a critical role in maintaining the homeostasis of AM and VDR-deficient AM are sufficient to induce pulmonary emphysema in wildtype mice.Fig. 4Accumulation of AM and development of emphysema *in Vdr*^−/−^ mice. **a**, Comparison of H&E staining of lung sections from 4- and 10-weeks old wildtype (WT) and *Vdr*^−/−^ littermates. **b**, Quantification of mean linear intercept (MLI) of alveolar airspace in WT and *Vdr*^−/−^ littermates. *n* = 3 per genotype and age group. **c**, Flow cytometry analysis of T and B cells from the lung tissues of WT and *Vdr*^*−/−*^ littermates at 4 weeks of age. Single cell suspension was prepared by digesting the lung tissue and stained for CD45, CD19, CD3, CD4, CD8, NK1.1 and CD44. Shown are representative CD19 *versus* CD3 staining profiles gating on CD45^+^ cells, CD4 *versus* CD8 staining profiles gating on CD3^+^ cells. Histograms show CD44 expression by CD4 T cells (left) and CD8 T cells (right) from WT (black) and *Vdr*^−/−^ (grey) mice. The results from the same staining of 10-week-old WT and *Vdr*^−/−^ mice are shown in Fig. S6a. **d**, Cells from BAL were stained for CD45, F4/80, CD11c, CD11b, MHCII and SiglecF. Shown are representative CD11c *versus* F4/80 staining profiles of CD45^+^ cells from WT and *Vdr*^−/−^ littermates at different ages. Expression of F4/80, MHCII, CD11b, CD11c and SiglecF by AM are shown in Fig. S6b. **e**, Comparison of AM numbers in the BAL of WT and *Vdr*^−/−^ mice at different ages (*n* = 6 mice each per genotype and age group). **f**, Inhibition of GM-CSF-induced AM proliferation by VD3. WT and *Vdr*^−/−^ AM were labeled with eFluor®670 and cultured in the presence of GM-CSF for two days with or without VD3. Shown are representative eFluor®670 histograms from one of the three experiments. A decrease in eFluor®670 intensity indicates cell proliferation. **g**-**i**, Induction of pulmonary emphysema by intratracheal transfer of *Vdr*^−/−^ AM into WT B6 mice. 5 × 10^5^ WT or *Vdr*^*−/−*^ AM (CD45.2^+^) were adoptively transferred into CD45.1^+^ B6 recipient mice every week for four weeks (*n* = 4 per group). At the 6th week, recipient mice were euthanized for flow cytometry to confirm the presence of the transferred cells in BAL (**g**) or H&E staining of lung sections (**h**) to quantify the mean linear intercept (MLI) of alveolar airspace (**i**). Scale bars in a and h: 100 μm. The numbers in **c**, **d** and **g** indicate percentages of cells in the gated regions. The arrows in **a** and **h** indicate enlarged alveolar space. Error bars indicate standard deviation (SD). *P* value was calculated by t-test. \* *P* \< .05, \*\* *P* \< .01, \*\*\* *P* \< .001.Fig. 4

3.4. VDR deficiency alters AM function {#s0100}
--------------------------------------

To investigate the molecular basis underlying the deregulated AM homeostasis in *Vdr*^−/−^ mice, we assayed the gene expression of AM from 4-week-old mice by RNA-seq. Differential expression analysis identified 130 up-regulated and 159 down-regulated genes in *Vdr*^−/−^ AM as compared to wildtype AM at a cutoff of 2-fold change with *P*-value \<.05 ([Fig. 5](#f0025){ref-type="fig"}a and Table S10). Functional enrichment analysis showed that altered genes in *Vdr*^−/−^ AM were involved in cell proliferation, ROS production, heme response, and cell immunity ([Fig. 5](#f0025){ref-type="fig"}b), consistent with the GESA results ([Fig. 5](#f0025){ref-type="fig"}c). The observation of up-regulation of genes involved in cell proliferation was consistent with the increased numbers of AM in *Vdr*^−/−^ mice. Both upregulation and downregulation of immune response genes were observed in *Vdr*^−/−^ AM while the expression of genes involved in response to IFNγ pathway were downregulated (Fig. S8), consistent with observations in AM from COPD patients \[[@bb0390]\]. Several COPD disease genes were also altered, including *Hmox1*, *Muc5b*, *Sftpb* and *Ccl5* ([Fig. 5](#f0025){ref-type="fig"}a), which were further validated by qPCR ([Fig. 5](#f0025){ref-type="fig"}d). Expression changes of several ECM-remodeling genes were also observed, including *Ctsk and Serpine1* (Fig. S9). Additional genes involved in COPD, fibrosis and tissue-remodeling were up-regulated in AM from 10 weeks old *Vdr*^−/−^ mice (Fig. S10). These results are consistent with a key role of AM in pulmonary emphysema in *Vdr*^−/−^ mice.Fig. 5VD3-VDR suppresses the basal and heme-dependent ROS in AM. **a**, Heatmap showing gene expression of 130 up-regulated and 159 down-regulated genes in *Vdr*^−/−^ AM as compared to WT AM from 4 weeks old mice. Shown is centralized CPM. **b**, GO enrichment analysis showing enrichment of certain pathways in the up-regulated and down-regulated genes. GO sets of biological process, number of genes and P-value are shown. **c**, GSEA showing enriched gene sets in *Vdr*^−/−^ AM (q-value \<0.05). **d**, Comparison of the transcript levels of *Hmox1*, *Muc5b*, *Sftpb*, *Ccl5* and *Irf4* in WT and *Vdr*^−/−^ AM by qPCR. **e**, Heme level in BAL of WT and *Vdr*^−/−^ mice at 5--7 weeks of age. n = 6--8 mice per group. **f**, Plot of VDR-binding scores of ROS-related genes and their expression change in *Vdr*^*−/−*^ AM. **g**-**h**, Comparison of ROS levels in WT and *Vdr*^*−/−*^ AM. WT and *Vdr*^*−/−*^ AM were cultured for 1 h in the absence or presence of heme and/or VD3. Intracellular ROS level was detected by CM-H2DCFDA and flow cytometry. Shown are representative histograms (**g**) of basal (left) and heme-induced (right) ROS level and summarized data (**h**) from three independent experiments. **i**, Comparison of ROS levels in human AM. AM from healthy individuals (*n* = 10) were cultured for 1 h in the absence or presence of heme and/or VD3. ROS level was assayed as in **g**. Statistical significance is calculated by t-test. \* P \< .05, \*\*P \< .01.Fig. 5

3.5. VD3-VDR axis suppresses heme-induced ROS in AM {#s0105}
---------------------------------------------------

Oxidative stress is known to play a significant role in COPD pathogenesis \[[@bb0395],[@bb0400]\]. Heme and iron are strong ROS inducers and are significantly elevated in BAL or serum of COPD patients and smokers \[[@bb0405],[@bb0410]\]. Similarly, heme level was significantly higher in BAL of *Vdr*^−/−^ mice than WT mice ([Fig. 5](#f0025){ref-type="fig"}e). We found that half of the genes involved in ROS and heme responsive pathways were directly bound by VDR in AM based on ChIP-seq ([Fig. 5](#f0025){ref-type="fig"}f). Consistently, VD3 suppressed the basal level as well as heme-induced ROS in AM and this effect was abolished in *Vdr*^−/−^ AM ([Fig. 5](#f0025){ref-type="fig"}g-h). Abundant ROS-induced DNA damage was detected in the lung sections of *Vdr*^−/−^ mice by anti-8OHdG staining (Fig. S11). Moreover, VD3 similarly suppressed heme-induced ROS in human AM ([Fig. 5](#f0025){ref-type="fig"}i). Taken together, these results suggest that the VD3-VDR axis suppresses both the basal and heme-induced ROS production in AM, consistent with the observed effect of VD3 in inhibition of COPD exacerbation.

3.6. VDR modulates LPS-induced gene expression in AM {#s0110}
----------------------------------------------------

Because of their anatomical location, AM are constantly exposed to external stimuli. We therefore investigated the role of the VD3-VDR axis in modulating gene expression in AM following LPS stimulation. Purified AM from B6 mice were stimulated with LPS for 4 h in the presence or absence of VD3, followed by RNA-seq. Differential expression analysis revealed 1985 genes with 2-fold or more change following LPS stimulation (LPS *vs.* control) and 516 genes with 2-fold or more change following LPS + VD3 stimulation (LPS + VD3 *vs.* LPS) ([Fig. 6](#f0030){ref-type="fig"}a and Table S11). Among the 516 genes, 276 genes were regulated by VD3 alone whereas the remaining 240 were regulated by both LPS and VD3 ([Fig. 6](#f0030){ref-type="fig"}b). To validate the regulation of LPS-induced genes by VDR, freshly isolated AM were stimulated with LPS for 4 h in the presence or absence of VD3. Quantitative RT-PCR showed that the transcript levels of pro-inflammatory genes, such as *Tnfa*, *Il1b*, *Cxcl2* and *Ccl5* were induced by LPS ([Fig. 6](#f0030){ref-type="fig"}c); but the induction was significantly inhibited by VD3. In contrast, anti-inflammatory genes, such as *Ccl2*, *Pdgfb* and *Irf4*, were up-regulated by VD3. Upregulation of *Irf4* by VD3 was further confirmed by flow cytometry and ChiP-seq in wildtype AM, whereas the upregulation was abolished in *Vdr*^−/−^ AM ([Fig. 6](#f0030){ref-type="fig"}d-e). VD3 also suppressed LPS-induced ROS in AM and this effect was abolished in *Vdr*^−/−^ AM (Fig. S12). Furthermore, we analyzed whether LPS-induced genes had VDR binding peaks in ChIP-seq data. Notably, \~35% (683 of 1985) of LPS-induced genes (*P* \< .05 plus \>2-fold change) in AM had VDR-binding peaks (*P* \< 1e-10 and peak score \> 30, [Fig. 6](#f0030){ref-type="fig"}f), including typical LPS-response genes, such as *Il1b* and *Ccl2* ([Fig. 6](#f0030){ref-type="fig"}a, g). Together, these data show that the VD3-VDR axis modulates AM response to LPS, by suppressing the expression of pro-inflammatory genes and up-regulating the expression of anti-inflammatory genes.Fig. 6VD3-VDR axis modulates gene expression in AM following LPS stimulation. **a**-**b**, Genome-wide transcriptional analysis of AM stimulated with LPS or LPS plus VD3 for 4 h. Heatmap (**a**) and overlap (**b**) of LPS-induced genes and VD3-induced genes in the presence LPS. LPS-induced genes were identified by comparison of LPS stimulation to control. VD3-induced genes were identified by comparison of LPS plus VD3 to LPS. **c**, Comparison of *Tnfa*, *Il1b*, *Cxcl2*, *Ccl5*, *Ccl2*, *Pdgfb* and *Irf4* transcript levels by qPCR in AM without any stimulation, with LPS or LPS plus VD3 stimulation for 4 h. **d**. Flow cytometry analysis of Irf4 intracellular staining in wildtype (WT) and *Vdr*^−/−^ AM with or without VD3 treatment for 24 h. **e**, Genome-browse of VDR-binding peaks in *Irf4* by IGV. **f**, Comparison of ChIP-seq peak scores of VDR-binding genes and LPS-induced genes (\>2-fold changes) in AM. **g**, Genome-browse of VDR-binding peaks in *Il1b* and *Ccl2* by IGV.Fig. 6

4. Discussion {#s0115}
=============

COPD is a complex disease with overlapping clinical phenotypes and pathologies, and poorly understood molecular and cellular mechanisms. In this study, we have examined the role of AM in COPD pathogenesis and the underlying molecular mechanisms. We show that VD3-VDR axis is critical for maintaining AM homeostasis and function and defect in this axis results in emphysema. First, VDR is highly expressed in AM (Fig. S3) and AM accumulate in *Vdr*^*−/−*^ mice ([Fig. 4](#f0020){ref-type="fig"}e). The accumulation is likely driven by GM-CSF induced proliferation because VD3 inhibited GM-CSF induced proliferation of wildtype but not *Vdr*^*−/−*^ AM ([Fig. 4](#f0020){ref-type="fig"}f). At molecular level, VD3 stimulated AM to express E2F-related cell cycle genes ([Fig. 2](#f0010){ref-type="fig"}b-c), which are known to inhibit cell proliferation. Thus, our finding identifies VD3 as a natural antagonist of GM-CSF for controlling AM homeostasis. Second, concomitant with the accumulation of AM, *Vdr*^*−/−*^ mice develop emphysema as early as 4 weeks of age. The critical role of *Vdr*^*−/−*^ AM in the observed pathogenesis was directly tested by intratracheal transfer of AM from *Vdr*^*−/−*^ mice into wildtype mice. The induction of emphysema in the recipient mice after 4 weeks suggests that dysfunctional macrophages alone are sufficient to induce the observed pathology. Notably, the development of emphysema in *Vdr*^*−/−*^ mice or recipient wildtype mice was not accompanied by apparent infiltration of immune cells into the lung tissue ([Fig. 4](#f0020){ref-type="fig"}), suggesting that the two key COPD pathologies - emphysema and bronchiolitis -- can be separated from each other. Our findings are consistent with observations that patients with emphysema and COPD exhibit dramatic increases in AM as compared to healthy individuals \[[@bb0045], [@bb0050], [@bb0055]\]. Development of emphysema has also been reported in old *Vdr*^*−/−*^ mice \[[@bb0185]\], which survived for \>16 weeks because of supplementation with calcium and phosphorus. What distinguish our study from the previous studies is that we delineated the causal effect between dysfunctional AM and development of emphysema.

Our comprehensive analyses of gene expression in wildtype and *Vdr*^*−/−*^ AM with or without VD3 treatment further reveal possible molecular mechanisms by which *Vdr*^*−/−*^ AM cause emphysema. VD3-VDR axis regulates the expression of over six hundred genes, including several COPD biomarkers such as *Hmox1* \[[@bb0415]\], *Muc5b* \[[@bb0420]\] and *Clec5a* \[[@bb0425]\]. Deficiency in VD3-VDR axis results in dramatic changes in gene expression. For example, extracellular matrix (ECM) remodeling enzymes play important roles in alveolar wall destruction during the pathogenesis of COPD \[[@bb0065]\]. Several of these enzymes are regulated by the VD3-VDR axis (Fig. S9). PAI-1 (*Serpine1*) and cathepsins K (*Ctsk*) were up-regulated in *Vdr*^−/−^ AM but down-regulated by VD3 in wildtype AM. PAI-1 is elevated in COPD patients and its polymorphism is associated with susceptibility to COPD \[[@bb0430],[@bb0435]\]. The cysteine protease cathepsins K, which is potent elastase and collagenase and capable to degrade ECM, is also up-regulated in emphysema patients and animal models \[[@bb0440]\]. Interestingly, another elastase MMP-12 was downregulated in *Vdr*^−/−^ AM but up-regulated by VD3 treatment of wildtype AM. MMP-12 is up-regulated in COPD patients \[[@bb0075],[@bb0445]\] and essential for the development of emphysema in mice following exposure to cigarette smoke \[[@bb0450]\]. However, MMP-12 is also involved in inflammation either directly or through the activation of TNFα and IFNα or inactivation of IFNγ \[[@bb0455], [@bb0460], [@bb0465], [@bb0470]\]. Oxidative stress is another major factor in the pathogenesis of COPD \[[@bb0400]\]. *Vdr*^*−/−*^ AM produced higher levels of ROS at the basal level or in response to heme or LPS and *Vdr*^*−/−*^ mice had higher levels of heme in BAL and ROS-induced lung damage, while VD3 treatment suppressed the ROS production of AM ([Fig. 6](#f0030){ref-type="fig"} and Fig. S12). The increased level of heme in BAL of *Vdr*^*−/−*^ mice is likely due to leakage and lysis of red blood cells in the lung due to tissue damage. Heme released from red blood cells could stimulate inflammatory response, including ROS production by AMs. The feedback between heme and ROS release could positively enforce each other in lung tissue damage. In addition, *Vdr*^−/−^ AM showed down-regulation of genes involved in pathways of immune response and response to IFNγ ([Fig. 5](#f0025){ref-type="fig"}b and Fig. S8), similar to alternatively activated AM from COPD patients \[[@bb0390]\]. Previous studies have also shown that the immune response pathways in human AM are modulated by VD3 *in vivo* and *in vitro* in the context of bacterial infection \[[@bb0475],[@bb0480]\], including some of validated genes (CCL2 and TNF) in mouse AM. Together, the increased numbers and dysfunction of AM could mediate the development of emphysema in *Vdr*^−/−^ mice.

Our study sheds light on the conflicting results from longitudinal and cohort studies of VD3 supplements in COPD patients. Although the large population-based studies of VD3 supplements on COPD measured the levels of vitamin D~3~ in the serum, none of the studies made the fine distinction between COPD patients with emphysema, obstructive bronchiolitis or both. Based on our finding that deficiency in the VD3-VDR axis leads to development of emphysema but not bronchiolitis, VD3 supplements would be expected to exert most benefit in COPD patients with VD3 deficiency and emphysema, whereas VD3 supplements may not have much effect on obstructive bronchiolitis. Lumping different patients with different COPD pathologies together may have masked the efficacy of VD3 supplements on emphysema. While our prediction needs to be verified, our study suggests new direction for longitudinal and cohort studies.

Our systems biology analyses identify key transcription factors (TF) for tissue-resident macrophages and disease genes. We developed regulatory network-based approaches to identify key TFs to understand tissue-specific programming of gene expression for seven different tissue macrophages, and functional network-based approaches to prioritize key disease genes associated with particular tissue macrophages. *Vdr* was predicted as top-1 key TF for AM and a key COPD disease gene (ranked 10th, [Fig. 1](#f0005){ref-type="fig"}e). Our follow-up studies confirmed that *Vdr* is required for AM homeostasis and function and dysregulation of this pathway specifically results in emphysema. Besides heterodimerization with RXR, VDR also interacts with Pu.1, Fra1 and Cebpa, and VD3 strongly promotes these interactions ([Fig. 3](#f0015){ref-type="fig"}g). Pu.1 and Fra1 are essential coactivators to maintain macrophage identity and phenotype \[[@bb0030],[@bb0345],[@bb0365]\], our results would suggest VDR recruits macrophage-specific coactivators to regulate AM homeostasis and function. *Pparg*, top 5th predicted key TF for AM, is induced by GM-CSF in fetal monocytes for their differentiation to AM, but not in mature AM \[[@bb0375],[@bb0485]\]. Previous studies have shown *Pparg* plays important roles in maintaining the phenotype and function of AM \[[@bb0380],[@bb0385]\] and activation of PPARG in AM inhibits inflammation in the cigarette-smoke exposed mice \[[@bb0490]\]. Similar to VDR, PPARG also forms a complex with RXR and binds to different DNA motifs to regulate gene expression in response to different ligands \[[@bb0495]\]. Interestingly, VD3 promotes the interaction between VDR and PPARG as shown by co-immunoprecipitation (Fig. S5). These findings suggest that VDR and PPARG may regulate the phenotype and function of AM in different stages through competing for their heterodimer RXR in the presence of different ligands. In addition, studies have shown that *Irf4* is an essential regulator required for maintaining M2 phenotype of tissue macrophages \[[@bb0500]\]. The expression of *Irf4* was significantly induced by VD3 through VDR binding to the *Irf4* promoter. Consistently, *Irf4* was down-regulated in *Vdr*^*−/−*^ AM as compared to wildtype AM ([Fig. 2](#f0010){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). Thus, VD3-VDR axis also maintains the M2 phenotype and function of AM partly through up-regulating expression of *Irf4* directly.

Our studies also identify the top-1 key TFs *Spic* for red pulp macrophages and *Gata6* for peritoneal macrophages. Both are known as the lineage-specific key TFs for the respective macrophage development and function \[[@bb0295], [@bb0300], [@bb0305], [@bb0310]\]. *Sox4* was predicted as top-1 key TF for microglia in our study. Sox4 is a target of TGF-β signaling \[[@bb0505]\] and TGF-β plays a critical role in microglia development *as its* deletion leads to the absence of microglia in mice \[[@bb0510]\]. Interestingly, microglia are present in *Csf1*^op/op^ mice but absent from *Csf1r*^*−/−*^ mice \[[@bb0515]\]. Deficiency of IL-34, another ligand of CSF1R, reduces microglia numbers \[[@bb0520]\]. These observations suggest *Sox4* is likely a key regulator for microglia and it would be interesting to investigate the roles of *Sox4* in development and function of microglia and how it interacts with signals from TGF-β and IL-34. Tissue macrophages play critical roles in homeostasis and exert diverse functions. Abnormal functional changes of tissue macrophages contribute to the development and progression of autoimmune disease, fibrosis and cancer \[[@bb0525],[@bb0530]\]. Identification of key TFs for tissue macrophages would help to understand the mechanisms by which they contribute to health and diseases.
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